Biotech Values

[miljenko]

< Why the disparity?>

It may be how each company see 214 batches, and needs for higher dose? BMY can not change what already started (they can add higher dose arm, as pleased), but for 1L NSCLC they need *clear cat* to compete with chemo-Pembro. Obviously PIVOT2 did not give them that (especially not for front line) and NKTR is stubborn (from initial term)! This may back-fire NKTR, lost time for any other PD-1 combo in NSCLC. BMY can still go after (NDA) 2L NSCLC PD-1 failed population with current dose (IF there is rationale and positive PIVOT2 data).

<Do we even know that MRK still wants to participate in a Keytruda + bempeg trial in NSCLC?>
No. No new update from trial. Roche and Merck were never involved in PROPEL trial, so who knows did Merck contacted (at all) Nektar on bempeg collaborative possibility?